NU7441 reveals DNA-PK and BRD4 convergence as a therapeutic vulnerability in ovarian cancer
Evidence is provided that NU7441, traditionally classified as a selective DNA-PK inhibitor, also functions as a BRD4 inhibitor by directly displacing BRD4 from acetylated chromatin and it is suggested that multi-target inhibition of BRD4 and DNA-PK can be leveraged to support new therapeutic strategies.